## **GREEN SHEET REDIGEST**

## HB 316

## 2021 Regular Session

Davis

CHILDREN/NEWBORNS: Adds mucopolysaccharidosis type I, glycogen storage disorder type II, and Krabbe disease to the state's newborn screening panel

\_\_\_\_\_

## DIGEST

<u>Present law</u> provides that a physician attending to the care of a newborn child shall cause the child to be subjected to a list of genetic conditions provided for in <u>present law</u> that have been approved by the La. Dept. of Health. Further provides that the genetic conditions shall be tested upon approval by the newborn child's parents.

<u>Proposed law</u> retains <u>present law</u> and adds that of the genetic conditions provided by <u>present</u> <u>law</u>, MPS I and Pompe diseases shall be genetic conditions approved by the La. Dept. of Health and shall be tested by physicians attending newborn children, upon the approval by the child's parents.

<u>Proposed law</u> supersedes amendments to <u>present law</u>, R.S. 40:1081.2(A)(1), made by §1 of Act No. 507 of the 2016 Regular Session.

Effective Jan. 1, 2022.

(Amends R.S. 40:1081.2(A)(1))

Summary of Amendments Adopted by House

The House Floor Amendments to the engrossed bill:

1. Provide for Krabbe disease to be added to the list of genetic conditions tested by physicians attending newborn children.

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Finance to the reengrossed bill

1. Removes Krabbe disease from the list of genetic conditions tested by physicians attending newborn children.